The U.S. Food and Drug Administration today revised its recommendations for rotavirus vaccines for the prevention of the disease in infants and has determined that it is appropriate forclinicians and health care professionals to resume the use of Rotarix and to continue the use of RotaTeq.
The agency reached its decision based on a careful evaluation
The FDA also considered the following in its decision:
Information for parents and caregivers is available on the web at:
Information for health care providers is available on the web at:
Media Inquiries: Shelly Burgess, 301-796-4651, email@example.com
/PRNewswire-USNewswire -- May 14/
SOURCE U.S. Food and Drug Administration
Subscribe to our Free Newsletters!